Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B

Tenofovir disoproxil fumarate (DF) is highly effective for the suppression of hepatitis B virus (HBV) in chronically infected adults. This study evaluated the safety and efficacy of tenofovir DF in adolescents with chronic hepatitis B (CHB). In this double‐blind, placebo‐controlled trial, adolescent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology (Baltimore, Md.) Md.), 2012-12, Vol.56 (6), p.2018-2026
Hauptverfasser:	Murray, Karen F., Szenborn, Leszek, Wysocki, Jacek, Rossi, Stephen, Corsa, Amoreena C., Dinh, Phillip, McHutchison, John, Pang, Phillip S., Luminos, Luminita M., Pawlowska, Malgorzata, Mizerski, Jacek
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - adverse effects Adenine - analogs & derivatives Adenine - therapeutic use Adolescent Alanine Transaminase - blood Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Biological and medical sciences Bone Density - drug effects Child DNA, Viral - blood Double-Blind Method Female Gastroenterology. Liver. Pancreas. Abdomen Hepatitis B Hepatitis B e Antigens - blood Hepatitis B Surface Antigens - blood Hepatitis B virus - genetics Hepatitis B virus - immunology Hepatitis B, Chronic - blood Hepatitis B, Chronic - drug therapy Hepatology Human viral diseases Humans Infectious diseases Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Organophosphonates - adverse effects Organophosphonates - therapeutic use Pharmacology. Drug treatments Tenofovir Viral diseases Viral hepatitis Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Tenofovir disoproxil fumarate (DF) is highly effective for the suppression of hepatitis B virus (HBV) in chronically infected adults. This study evaluated the safety and efficacy of tenofovir DF in adolescents with chronic hepatitis B (CHB). In this double‐blind, placebo‐controlled trial, adolescents 12 to
ISSN:	0270-9139 1527-3350
DOI:	10.1002/hep.25818